Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: A GISL cohort study

Haematologica

Volumn 93, Issue 9, 2008, Pages 1335-1342

  Sacchi, Stefano ^a,f   Marcheselli, Luigi ^a   Bari, Alessia ^a   Marcheselli, Raffaella ^a   Pozzi, Samantha ^a   Gobbi, Paolo G ^b   Angrilli, Francesco ^c   Brugiatelli, Maura ^d   Musto, Pellegrino ^e   Federico, Massimo ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c SPIRITO SANTO HOSPITAL   (Italy)

^d Azienda Ospedaliera Papardo   (Italy)

^e REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^f UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Diffuse large B cell lymphoma; DLBCL; Non Hodgkin's lymphoma; Risk factors; Second malignancies; Treatment

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FOLINIC ACID; IDARUBICIN; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEMOGRAPHY; DIGESTIVE SYSTEM CANCER; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; LABORATORY TEST; LARGE CELL LYMPHOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OVARY CANCER; PROSTATE CANCER; SECOND CANCER; SKIN CANCER; STOMACH CANCER; TESTIS CANCER; VULVA CANCER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; RISK FACTORS;

EID: 50849120747     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.12918     Document Type: Article

References (39)

1. Swerdlow AJ, dos Santos Silva I, Doll R. Cancer incidence and mortality in England and Wales: trends and risk factors. Oxford, United Kingdom Press, 2001.
2. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;24:235-42.
3. Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL, Chrischilles E, Link BK. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005;23:5019-26.
4. Fisher RI, LeBlanc M, Press OW Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005;23:8447-52.
5. Liu Q, Cabanillas F, Hagemeister F B, Ayers GD, Hess M, Romaguera J, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at the University of Texas M. D. Anderson Cancer Center. J Clin Oncol 2006;24:1582-9.
6. Sacchi S, Pozzi S, Marcheselli L, Bari A, Luminari S, Angrilli F, et al. Introduction of rituximab in frontline and salvage therapies has improved outcome of advancedstage follicular lymphoma patients. Cancer 2007;109:2077-82.
7. Travis LB, Curtis RE, Glimelius B, Holowaty E, Van Leeuwen FE, Lynch CF, et al. Second cancer among long-term survivors of non Hodgkin's lymphoma. J Natl Cancer Inst 1993;85:1932-6.
8. Brennan P, Coates M, Amstrong B, Colin D, Boffetta P. Second primary neoplasms following non-Hodgkin's lymphoma in New South Wales, Australia. Br J Cancer 2000;82:1344-7.
9. Dong C, Hemminki K. Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958-1996: a search for common mechanisms. Br J Cancer 2001;85:997-1005.
10. Mudie NY, Swerdlow AJ, Higgins CD, Smith P, Qiao Z, Hancock BW et al. Risk of second malignancy after non-Hodgkin's lymphoma: a British Cohort Study. J Clin Oncol 2006;24:1568-74.
11. Brennan P, Scèlo G, Hemminki K, Mellemkjaer L, Tracey E, Andersen A, et al. Second primary cancer among 109000 cases of non-Hodgkin's lymphoma. Br J Cancer 2005;93:159-66.
12. Tward JD, Wendland MM, Shrieve DC, Szabo A, Gaffney DK. The risk of secondary malignancies over 30 years after treatment of non-Hodgkin lymphoma. Cancer 2006;107:114-8.
13. Sacchi S, Marcheselli L, Bari A, Marcheselli R, Pozzi S, Luminari S, et al. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. Haematologica 2008;93:392-8.
14. Okines A, Thomson CS, Radstone CR, Horsman JM, Hancock BW. Second primary malignancies after treatment for malignant lymphoma. Br J Cancer 2005;93:418-24.
15. Andrè M, Mounier N, Leleu X, Sonet A, Brice P, Henry-Amar M, et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood 2004;103:1222-8.
16. Moser E, NoordiJk EM, Van Leeuwen FE Baars JW, Thomas J, Carde P, et al. Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma, an EORTC cohort study. Haematologica 2006;91:1481-8.
17. Federico M, Gobbi PG, Avanzini P, Bertoloni D, Cavanna L, Dini D, et al. ProMACE-CytaBOM in treatment of intermediate and high grade non Hodgkin's lymphomas. New insights in lymphomas. 1st Vicenza International Workshop of Hematology, June 1989.
18. Silingardi V, Federico M, Capanna L, Avanzini P, Gobbi PG, Lombardo M, et al. ProMECE-CytaBOM vs MACOP-B in aggressive non-Hodgkin's lymphoma: long term results of a multicenter study of the Italian Lymphoma Study Group (GISL). Leuk Lymphoma 1995;17:333-20.
19. Federico M, Clò V, Brugiatelli M, Carotenuto M, Gobbi PG, Vallisa D, et al. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL. Haematologica 1998;83:800-11.
20. Federico M, Luminari S, Gobbi PG, Sacchi S, Di Renzo N, Lombardo M, et al. The length of treatment of aggressive non-Hodgkin's lymphomas established according to the International Prognostic Index score: long-term results of the GISL LA03 study. Eur J Haematol 2006; 76:217-29.
21. Gobbi PG, Ghirardelli M, Avanzini P Baldini L, Quarta G, Stelitano C, et al. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with three-fold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian Lymphoma Study Group (GISL). Haematologica 2000;85:263-8.
22. Gobbi PG, Broglia C, Valentino F, Mammi C, Lombardo M, Merli F, et al. The role of dose size in a chemotherapy regimen (ProMACE-CytaBOM) for the first-line treatment of B-cell lymphomas: a randomized trial by the Gruppo Italiano Studio Linfoma (GISL). Ann Oncol 2006;17:676-82.
23. Di Renzo N, Luminari S, Montanini A, Petrini, Gobbi PG Stelitano C, et al. Early response to a short course of induction chemotherapy overcomes the prognostic role of IPI in patients with aggressive NHL. Preliminary results of GISL LA05 trial. Blood 2005;108 abstract # 612.
24. Gobbi P, Ghirardelli ML, Cavalli C, Baldini L, Broglia C, Clò V, et al. The role of surgery in the treatment of gastrointestinal lymphomas other than low-grade MALT lymphomas. Haematologica 2000;85:372-80.
25. Merli F, Bertini M, Luminari S, Mozzana R, Botto B, Liberati AM, et al. Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2007;48:367-73.
26. Merli F, Bertini M, Sacchi S, Liberati AM, Malorgio F, Vitolo U, et al. A pilot study with an oral chemotherapy regimen (CIEP) in the treatment of diffuse large cell lymphoma (DLCL) in elderly patients: an interim report from Italian Lymphoma Intergroup (ILI). Ann Oncol, 13 (Suppl 2) 2002, Ab 554.
27. Merli F, Vitolo U, Luminari S, Mazza P, Stelitano C, Rossi G, et al. R-CHOP vs R-mini-CEOP in elderly patients with diffuse large B cell lymphoma: an interim report from Intergruppo Italiano Linfomi (ILL). Blood 2005; 106 abstarct # 4729.
28. World Health Organisation. Manual of the international statistical classification of disease, injuries and causes of death: based on the recommendations of the Ninth Revision Conference, 1975, and adopted by the Twenty-ninth World Health Assembly, Vol. I. Geneva: World Health Organisation, 1977: http://www.cdc.gov/nchs/icd9.htm
29. Istituto Superiore di Sanità (http://www.iss.it).
30. Clayton DG, Hills M. Statistical models in epidemiology. 1993 Oxford: Oxford University Press.
31. Breslow NE, Day NE. Statistical methods in cancer research - Vol. II: The design and analysis of cohort studies. 1987; IARC Scientific Publication N. 82. p. 91-8.
32. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18:695-706.
33. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141-54.
34. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
35. R version 2.3.1: Copyright 2006, The R Foundation for Statistical Computing, http://cran.r-project.org/.
36. StataCorp. 2003. Stata Statistical Software: Release 8. College Station, TX: StataCorp LP.
37. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987.
38. Travis LB. Evaluation of the risk therapy-associated complication in survivors of Hodgkin lymphoma. ASH Educational Program Book 2007;192-7.
39. Travis LB, Hill D, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005;97:1428-37.